---
title: Image brain alpha synuclein deposition
nct_id: NCT07348250
phase: EARLY_PHASE1
status: RECRUITING
sponsor: Invicro
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07348250"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07348250"
last_fetched: "2026-05-10T14:07:20.716Z"
source: "Parkinson's Pathways (curated)"
---
# Image brain alpha synuclein deposition

**Goal (in five words):** Image brain alpha synuclein deposition

**Official Title:** An Open-label Study to Evaluate Brain α-Synuclein Deposition Using Positron Emission Tomography (PET) and [18F]MK-0947 in Patients With Parkinson's Disease

**Trial ID:** [NCT07348250](https://clinicaltrials.gov/study/NCT07348250)

## Key Facts

- **Phase:** EARLY_PHASE1
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Invicro
- **Target Enrollment:** 22 participants
- **Start Date:** 2025-12-08
- **Completion Date:** 2026-10
- **Conditions:** Parkinson's Disease (PD), Parkinson's Disease, Parkinson's Disease (Disorder)
- **Interventions:** [18F]MK-0947
- **Intervention Types:** DRUG

## Summary For Families

The goal is to find out whether a new PET tracer, [18F]MK-0947, can reliably show alpha-synuclein protein deposits in the brain of people with Parkinson's, which could help diagnose and track the disease. Participants receive a small injection of the radioactive tracer that binds to alpha-synuclein aggregates and is imaged with PET, often with MRI; the tracer is for imaging only, it does not treat Parkinson's and generally does not interfere with medications like levodopa. The study is enrolling adults 40 to 80 years old with Parkinson's and healthy older volunteers, plus a smaller group of healthy people aged 18 to 50, and requires informed consent, ability to tolerate PET/MRI and possible arterial sampling, no major medical issues, and not being pregnant.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Signed informed consent prior to any study procedures
* Women of childbearing potential: abstinent or use 2 contraception methods (one barrier) during study and 90 days post last injection
* Men: use 2 contraception methods and refrain from sperm donation during study and 90 days post last injection
* PD \& HE participants: Age 40-80 years; HP participants: Age 18-50 years
* Adequate circulation and normal clotting for arterial cannulation (if applicable)
* HE participants: no neurological disorder, no first-degree relative with idiopathic PD
* HP participants: healthy with no clinically relevant findings

Exclusion Criteria:

* Unwilling or unable to provide informed consent
* Clinically significant hepatic, renal, cardiovascular, pulmonary, or systemic illness
* Pregnant or breastfeeding
* Contraindication to PET or MRI procedures (e.g., implants, claustrophobia)
* History of severe allergic reactions to PET tracers or related compounds
* Current or prior participation in investigational drug study within 30 days
* Any condition that may interfere with study conduct or participant safety
```

## Locations (1)

- Invicro (dba Perceptive), New Haven, Connecticut, United States _(41.3081, -72.9282)_
  - David Russell, M.D., Ph.D — (CONTACT) — 203-401-4300 — learnmore@perceptive.com
  - (CONTACT) — learnmore@perceptive.com

## Central Contacts

- David Russell, MD, PhD — (CONTACT) — 203-401-4300 — learnmore@perceptive.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07348250*  
*HTML version: https://parkinsonspathways.com/trial/NCT07348250*  
*Source data: https://clinicaltrials.gov/study/NCT07348250*